Related Experiment Video
Updated: Feb 5, 2026
A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
Published on: October 16, 2018
The promise of CAR T-cell therapy in aggressive B-cell lymphoma
Ranjit Nair1, Sattva S Neelapu1
1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.
Abstract:
Relapsed or refractory aggressive B-cell lymphoma has an extremely poor prognosis and efforts to develop novel therapies for these patients have failed for almost four decades until the advent of chimeric antigen receptor (CAR) T-cell therapy. Within the last one year, two anti-CD19 CAR T-cell therapy products, axicabtagene ciloleucel and tisagenlecleucel, were approved by the United States Food and Drug Administration for the treatment of relapsed or refractory large B-cell lymphoma after at least two lines of systemic therapy based on multicenter single-arm phase two clinical trials. Here, we will discuss the different components of the CAR construct and their mechanisms of action, the role of conditioning chemotherapy, the efficacy and toxicity observed with anti-CD19 CAR T-cell therapies in aggressive B-cell lymphomas, and emerging strategies to further improve the safety and efficacy of these highly promising approaches.
Insights
Chimeric antigen receptor (CAR) T-cell therapy offers new hope for aggressive B-cell lymphoma patients. Approved anti-CD19 CAR T-cell therapies show promise in treating relapsed or refractory disease.
Area of Science:
- Hematology
- Oncology
- Immunotherapy
Background:
- Aggressive B-cell lymphomas, particularly relapsed or refractory cases, present a significant unmet medical need with limited therapeutic options for nearly four decades.
- The development of novel therapies has been challenging, highlighting the critical need for innovative treatment strategies.
Purpose of the Study:
- To review the components and mechanisms of chimeric antigen receptor (CAR) T-cell constructs.
- To discuss the role of conditioning chemotherapy in CAR T-cell therapy.
- To summarize the efficacy and toxicity of anti-CD19 CAR T-cell therapies in aggressive B-cell lymphomas and explore future improvements.
Main Methods:
- Review of recent clinical trial data for approved anti-CD19 CAR T-cell products.
- Discussion of the biological components and action of CAR T-cells.
- Analysis of safety and efficacy profiles from phase two clinical trials.
Main Results:
- Two anti-CD19 CAR T-cell therapies, axicabtagene ciloleucel and tisagenlecleucel, have been FDA-approved for relapsed/refractory large B-cell lymphoma.
- These therapies demonstrated efficacy in multicenter, single-arm, phase two clinical trials.
- Observed toxicities and efficacy data are crucial for understanding treatment outcomes.
Conclusions:
- CAR T-cell therapy represents a breakthrough in treating aggressive B-cell lymphomas.
- Further research is ongoing to optimize safety and efficacy of these advanced immunotherapies.
- Emerging strategies aim to enhance the therapeutic potential of CAR T-cell approaches.
Related Concept Videos
01:47Aggression
01:21Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
00:59Gene Therapy
01:21Secondary Motives: Affiliation Motivation and Aggression Motivation
01:26Group Therapy
01:07What are Cells?
Basic Characteristics of Cells
A living cell has a plasma membrane, a bilayer of lipids that separates the aqueous solution inside the cell called the cytoplasm from the outside environment.
Furthermore, a living cell possesses genetic information...